We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Technology

Celsium  

Status: Active

Jun 23rd 2020

SMARTR Health Limited, also called Celsium, is a medical technology company. It has developed the world’s first medical-grade device that continuously measures core temperature, both accurately and non-invasively, through a combination of a wearable sensor and a smart platform. Intended for use in the formal healthcare sector, as well as at home, it has been classified as a CE Class 2A medical device in the EU and as an FDA 510K medical device in the US. In a clinical study, conducted in collaboration with Boston Children’s Hospital and Cleveland Clinic, the company's product showed promising results 10-20 times more accurate than current devices. Celsium has experienced a surge in demand due to Covid-19, where fever is a key symptom. This, the company argues, is a perfect time to accelerate its business plan.

read more read less

Celsium   Rating Review

Rated on 13/07/2020

Pitch Rated

80%

Gold

Management

80%

Product

77%

Investment

84%

Pitch rating powered by CROWDRATING

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating
Click here for more information on our ratings
Login to view the full report

Management 80%

Skills 82%
Celsium's management team are driven by a desire to improve people's health and quality of life through innovative technology. The CEO is skilled in Account Management, Business Development, and has been involved in the development and commercialisation of new medical products and the management of multimillion-pound P&Ls. Their CTO is a successful technology leader with a proven record of delivery in roles spanning product management, architecture, and development. His passion is to design innovative technology solutions that delight customers and solve problems and is skilled in machine learning and cloud computing. The CPO has a deep understanding of the complete technical product lifecycle from concept to operational support. The COO is skilled in Leadership, International Networking, Medical Research, and has been the CEO and Managing Director of several software and management consulting companies. Also, the team is supported by a dedicated CFO who has in-depth knowledge in all the aspects of financial management, both internal and external, across a variety of industries. She has a proven track record of managing a variety of large scale projects (both revenue and capital).

0 comments

Log in to comment


Funding progress

not enough data

More from Technology

Coinrule is a smart assistant designed for millennials looking to automate their investments in cryptocurrencies, financial assets and build trading strategies without having to program a single line of code. The platform empowers regular traders and investors to compete with professional algorithmic traders and hedge funds. Users can pick 'building blocks' via a simple interface to create trading strategies which also get backtested on historical data. The company aims to make trading an accessible option for all. It has 13,000+ registered users on its portal, witnessed a $3.3 million Monthly Trading Volume (MTV) in July 2020 despite the COVID-19 pandemic, and raised a pre-seed of £200,000 from MKB Bank and two Angel Investors (AI) in 2019. It also won the ‘Best for Beginners 2020’ award by Cryptotrader. The company will use the investment to become a reliable investment ecosystem for users, activate paid growth channels based on influencer marketing and direct acquisition, validate upcoming product offerings, and keep building a strong interdisciplinary team.
pledged: 107% days to go: 39 investment: £269,306
Themis is a Regulatory Technology (RegTech) company that helps organisations mitigate the risk and impact of all forms of financial crime such as money laundering, bribery, corruption, cybercrime, theft, slavery/human trafficking, and fraud. The RegTech sector is expected to become a GBP 10 billion industry at the end of 2020. Themis aims to be a major contender in this segment and also plans to stop financial frauds that it asserts costs companies globally GBP 3.2 trillion every year. The platform is designed to provide insights on the latest threats, trends, and criminal techniques whilst helping clients complete due diligence on their clients, staff, and supply chains. Themis's key clients include Dow Jones, TSB, Fiserv, Mitmark, Ebury, Natwest Group, Acuris, Glasswall, Evolution AI, and Kingley Napley amongst others. The company envisages exiting via an Initial Public Offering (IPO) or selling to a technology company or to a big consultancy wanting to have a specialized Financial Crime (FC) arm to their business, including a RegTech solution
pledged: 37% days to go: 85 investment: £567,027
Invisage is a cloud-based platform that helps asset managers optimise their performance and research costs by identifying the true value of investment research. The company asserts that Directive 2014/65/EU has led to the investment research market falling from $16.5 billion to $14 billion as managers look to reduce costs and increase value. Invisage asserts that its platform helps asset managers identify, objectively measure ‘value’ added by research, and consume only high-impact research. The company also offers a web-based research consolidation, valuation and attribution solution that gives a quantitative assessment of value added by research to client portfolios. Invisage will use the investment to enhance deep learning-based Natural Language Processing (NLP) models that detect the implicit ideas from research narrative, build partnerships with data providers and other solution providers, and market scale its sales function
pledged: 75% days to go: 85 investment: £75,000
Superpow! is an online therapy platform that intends to shift away from the conventional and clinical form of mental health treatment. It is a platform that aims to help users find a matching therapist based on factors such as preferred language, ethnical background, sexual orientation, gender, age, symptoms. The app endeavours to match a user with a therapist quicker than any other app. The company estimates that 70 million workdays are lost each year due to mental health problems in the UK, costing employers approximately £2.4 billion per year. This scenario is further exacerbated due to COVID-19. Superpow! aims to change this situation. It will use the investment to finalise app development, scale the business within the UK as well as Europe, and enter the US market.
pledged: 46% days to go: 22 investment: £23,335
Phlo is a digital pharmacy portal. Founder Nadeem Sarwar launched Phlo in 2019 after having faced the challenges with obtaining prescription medication from retail stores where there was either no stock or long waiting times. Phlo aims to become the UK’s leading on-demand 'Digital Pharmacy' platform. It is integrated with the National Health Service's (NHS) accredited systems and enables patients living within the London area to order and receive their medication within a 4-hour window. Phlo serves more than 4000 patients from Orkney to Jersey. It has received a 5- star rating on Trustpilot and secured a contract with Babylon, a leading UK-based telemedicine provider. Phlo will use the investment to grow its business across different verticals and become one of the UK’s leading digital pharmacies.
pledged: 110% days to go: 22 investment: £1,815,430

  • Withheld
    pledged

    £752,500
    target

    £9,846,092
    pre-money valuation

    7.10%
    equity available

    Withheld
    investors

    Withheld
    pledge per investor

    11416421
    company number

    Active
    company status

    14/06/2018
    incorporated 2 years

    Equity Calculator
    Investment
    £
    Equity
    %
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph